ArticleClinicoEconomics and outcomes research : CEOR2014

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis.

Thitima Kongnakorn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.